Global CBRN Medical Countermeasures Market

Table of Content

1. Executive Summary

2. Market Research Methodology
2.1. Research methodology and design
2.2. Sample selection
2.3. Reliability and validity

3. Market Analysis
3.1. Market size and growth rates
3.2. Macroeconomic change
3.3. Market growth drivers, market dynamics and trends
3.4. Megatrends and their impact
3.5. Value chain analysis
3.6. Market scenarios and opportunity forecasts
3.7. Relevant markets
3.8. The new frontiers of growth
3.9. Creating value through sustainable strategies

4. Market Breakdown by Component
4.1. Introduction
4.2. Therapeutics
4.2.1. Antidotes
4.2.2. Antimicrobials
4.2.3. Radiation mitigators/treatments
4.2.4. Antitoxins
4.2.5. Supportive care drugs
4.3. Vaccines
4.3.1. Pre-exposure prophylaxis for specific biological threats
4.3.2. Vaccines for select toxins
4.4. Diagnostics
4.4.1. Rapid diagnostic tests
4.4.2. Laboratory-based diagnostic assays
4.4.3. Biodosimetry devices
4.4.4. Detection kits

5. Market Breakdown by Threat Type
5.1. Introduction
5.2. Chemical Agents
5.2.1. Nerve Agents
5.2.2. Blister Agents
5.2.3. Blood Agents
5.2.4. Choking Agents
5.2.5. Incapacitating Agents
5.2.6. Toxic Industrial Chemicals (TICs) / Toxic Industrial Materials (TIMs)
5.3. Biological Agents
5.3.1. Bacterial Threats
5.3.2. Viral Threats
5.3.3. Biological Toxins
5.3.4. Marine Toxins
5.4. Radiological/Nuclear
5.4.1. Acute Radiation Syndrome (ARS) specific MCMs
5.4.2. Delayed Effects of Acute Radiation Exposure (DEARE) MCMs
5.4.3. Internal Contamination Treatments
5.4.4. Radioprotectants/Radiomitigators

6. Market Breakdown by Application
6.1. Introduction
6.2. Medical Countermeasures (MCMs)
6.2.1. Post-exposure and prophylactic treatments
6.2.2. Drug Development for CBRN threats
6.2.3. Vaccines, Therapeutics, and Diagnostics tailored to CBRN
6.3. Detection and Diagnostics
6.3.1. Early Detection Tools for CBRN Threats
6.3.2. Biochemical/Genetic Diagnostic Platforms
6.3.3. Integration with Government and Military Threat Response Systems
6.4. Decontamination and Mitigation
6.4.1. Technologies for Chemical, Biological, and Radiological Decontamination
6.4.2. Emergency Mitigation Therapies for CBRN Exposure

7. Market Breakdown by End User
7.1. Introduction
7.2. Government Agencies
7.2.1. National Stockpiles
7.2.2. Defense/Military Agencies
7.2.3. Public Health Agencies
7.2.4. Emergency Response Agencies
7.3. Healthcare Providers
7.3.1. Hospitals and Clinics (for direct patient care in a CBRN event)
7.3.2. Emergency Medical Services (EMS)
7.4. Research & Development Institutions
7.4.1. Academic Research Centers
7.4.2. Biotechnology and Pharmaceutical Companies

8. Market Breakdown by Geography
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Russia
8.3.5. Italy
8.3.6. Spain
8.3.7. Sweden
8.3.8. Switzerland
8.3.9. Netherlands
8.3.10.Others
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. South Korea
8.4.4. India
8.4.5. Australia
8.4.6. Others
8.5. Middle East & Africa
8.5.1. South Africa
8.5.2. Saudi Arabia
8.5.3. UAE
8.5.4. Israel
8.5.5. Others

9. Competitive Landscape
9.1. Competitive situation and trends
9.2. Industry benchmarking
9.3. Maintaining current market share
9.4. Expansion path
9.5. Recent market and industry developments
9.5.1. New product developments and announcements
9.5.2. Agreements, partnerships, joint ventures, and collaborations
9.5.3. Mergers and acquisitions and major PE deals

10. Companies Profiled
10.1.Amgen Inc.
10.2.AstraZeneca
10.3.Baxter International
10.4.Elusys Therapeutics
10.5.Emergent BioSolutions
10.6.Humanetics Corporation
10.7.Kindeva Drug Delivery
10.8.Lawrence Livermore National Laboratory
10.9.Lyndra Therapeutics
10.10.Novartis
10.11.PharmAthene
10.12.Pluri Inc.
10.13.SIGA Technologies
10.14.Soligenix Inc.
10.15.SRI International
10.16.Vaxart
10.17.Others

Request Sample

Buy Now